Metabolic engineering is the enabling technology to rewire cellular endogenous metabolism for the optimal production of native metabolites, or endow cells with the capacity for synthesizing nonnative chemicals.^[@ref1]^ To date, there are numerous studies of engineering microbes for production of commodity chemicals and natural products, including the production of cannabinoids,^[@ref2]^ artemisinin,^[@ref3]^ taxol precursors,^[@ref4],[@ref5]^ branched-chain alcohols,^[@ref6],[@ref7]^ ornithine,^[@ref8]^ arginine,^[@ref9]^ advanced biofuels,^[@ref10]−[@ref13]^ and so on, from different host organisms. The primary goal of metabolic engineers is to achieve high titer, yield, and productivity (TYP) with improved cost-efficiency and process economics.^[@ref14],[@ref15]^ In the past decades, a number of prominent metabolic engineering strategies and methodologies have been adopted to balance or redirect metabolic flux, such as modular pathway engineering,^[@ref10]^ dynamic pathway regulation,^[@ref16]−[@ref19]^ cofactor engineering,^[@ref20],[@ref21]^ and scaffold-guided spatial colocalization of metabolic enzymes,^[@ref22],[@ref23]^*et al.* The spatiotemporal or ratiometric control of enzyme expression have been proven as efficient strategies to relieve metabolic burden and improve the TYP index.

However, the complex and lengthy synthetic routes from the starting carbons, such as glucose, commonly generate low yield and suboptimal productivity of desired products, which could be attributed to that complex biosynthesis requires the coordinated supply of precursors, ATPs, and reducing equivalents (NADPH/NADH) to maintain both cell metabolism and product formation.^[@ref24],[@ref25]^ Substrates with different entry points into the metabolic network have different energetic and redox statuses,^[@ref24],[@ref26]^ which leads to pathway-dependent product yields that critically affect cost-efficiency. Thus, providing microbes with multiple carbon sources can potentially mitigate these metabolic constraints, since it adds an additional degree of freedom to cellular systems that can be leveraged for product formation (namely, cosubstrate feeding).^[@ref26]^ One recent example is to use the acetate-driven acetyl-CoA metabolic shortcut to bypass the lengthy and highly regulated glycolytic pathway for efficient polyketides^[@ref27]^ and lipids production.^[@ref24]^ Such substrate doping strategy may present a metabolic advantage over a single substrate and lead to metabolic optimality beyond what can be achieved in single substrate fermentations. In other words, single substrate strategies may not be suitable for particular metabolic engineering applications. Instead, metabolite doping or cosubstrate feeding can overcome intrinsic pathway limitations and achieve high carbon conversion efficiency and cost-efficiency.

2-Phenylethanol (2-PE) is a high-value compound widely used in the food, fragrance, and flavor industries. High-quality 2-PE is primarily extracted from the volatile oil components of rose flower, with a marketed price ranging from \$150/kg to \$200/kg, which suffers from economics and scalability issues for sustainable production.^[@ref28]^ Chemically synthesized 2-PE, despite its low-cost and high conversion rate, is largely rejected by consumers and IFF society (International Flavors & Fragrances) due to safety and health issues.^[@ref29]^ As a result, heterologous production of 2-PE from microbial host is considered as an economically viable alternative to plant extraction. Herein, *Yarrowia lipolytica* was chosen as the host strain because of its strong acetyl-CoA flux and high TCA metabolic activity and the ease of genetic toolbox,^[@ref30]^ as demonstrated by its superior performance for production of advanced biofuels and oleochemicals.^[@ref31]^ In addition, *Y. lipolytica* is also a "Generally Regarded As Safe" (GRAS) organism in the food and nutraceutical industry.^[@ref32]^

To demonstrate the utility of substrate cofeeding, we harnessed the Ehrlich pathway of *Yarrowia lipolytica* to optimize the biosynthesis of 2-phenylethanol (2-PE), with glucose and [l]{.smallcaps}-phenylalanine as the cosubstrates. The bioconversion process involves deamination, decarboxylation, and aldehyde reduction ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), with several aromatic byproducts branched out from this pathway ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). In particular, the deamination is an α-ketoglutarate (aKG)-coupled amino transfer reaction and aldehyde reduction is a NADH-dependent reduction reaction ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Both the aKG and NADH, as cofactors, are derived from glucose. To improve the precursor flux and maximize 2-PE production, we have applied a stoichiometric model to determine the pathway yield and predict engineering targets ([Supplementary Note](http://pubs.acs.org/doi/suppl/10.1021/acssynbio.9b00468/suppl_file/sb9b00468_si_001.pdf)). To improve the overall pathway specificity, we characterized and reconfigured all the biochemical reactions in Ehrlich pathway by stepwise pathway refactoring more than 20 enzymes, and further blocked the competing pathways to eliminate any byproducts. On the other hand, cytosolic 2-oxoglutarate (aKG) is the cofactor to complete the amine transfer reaction. But aKG is derived from the oxidative decarboxylation of isocitrate that is primarily compartmentalized in mitochondria, creating a bottleneck for efficient assimilation of [l]{.smallcaps}-Phe, which limits 2-PE production. To improve metabolite trafficking across the mitochondria membrane, we constructed an artificial aKG source pathway in the cytosol, by coupling a cytosolic aconitase with the overflowed citrate from mitochondria. In addition, we further improved the aKG supply and 2-PE production by mitigating fatty acid synthesis. As a result, the engineered strain **(po1fk7P**) produced 2669.54 mg/L of 2-PE with 0.702 g/g conversion yield from [l]{.smallcaps}-Phe, representing about 4.16-fold and 2.07-fold increase over the starting strain (641.59 mg/L of 2-PE production with 0.339 g/g~[l]{.smallcaps}-phenylalanine~), respectively. Taken together, refactoring critical enzymes and increasing metabolite trafficking as well as mitigating competitive pathways are effective strategies to improve the efficiency of overall pathway yield.

![Central carbon metabolism and Ehrlich pathway for synthesizing 2-PE in *Y. lipolytica*. [l]{.smallcaps}-Phe, [l]{.smallcaps}-phenylalanine; PPY, phenylpyruvate; PAH, phenylacetaldehyde; *GapY3*, [l]{.smallcaps}-phenylalanine specific permease; *ylARO8*, [l]{.smallcaps}-phenylalanine transaminases; *ylHPD*, 4-hydroxyphenylpyruvate dioxygenase; *ylPHA2*, prephenate dehydratase; *ylARO10*, phenylpyruvate decarboxylase; *ylPAR4*, phenylacetaldehyde reductases; *ALD2,3*, aldehyde dehydrogenase; G6P, glucose-6-phosphate; F6P, fructose 6-phosphate; GAP, glyceraldehyde-3-phosphate; 3PG, 3-phospho-glycerate; PEP, phosphoenolpyruvate; aKG, 2-oxoglutarate; DAHP, 3-deoxy-arabino-heptulonate-7-phosphate; SHIK, shikimate ; S3P, shikimate-3-phosphate; [l]{.smallcaps}-Tyr, [l]{.smallcaps}-tyrosine; [l]{.smallcaps}-Typ, [L]{.smallcaps}-tryptophan; *ARO3,4*, 3-deoxy-7-phosphoheptulonate synthase; *ylODC*, 2-oxodicarboxylate carrier; *ylIDP2*, cytosolic isocitrate dehydrogenase; *EcoacnA*, aconitate hydratases; *DGA1,2*, diacylglycerol acyltransferase;](sb9b00468_0001){#fig1}

Results and Discussion {#sec2}
======================

Characterization of Ehrlich Pathway for 2-PE Synthesis in *Y. lipolytica* {#sec2.1}
-------------------------------------------------------------------------

Microbially produced 2-PE is mainly obtained by two routes, namely, the *de novo* pathway from glucose and bioconversion from [l]{.smallcaps}-phenylalanine by the Ehrlich pathway. Owing to the hard-wired, tightly complex feedback regulation^[@ref33]^ and lengthy reaction steps (\>20 steps) of the *de novo* pathway, bioconversion by the Ehrlich pathway is considered as the preferred biological route to synthesize 2-PE.^[@ref28]^ In the Ehrlich pathway ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), [l]{.smallcaps}-phenylalanine is converted to 2-PE through four enzyme-dependent processes: (i) extracellular [l]{.smallcaps}-phenylalanine is internalized by amino permeases; (ii) [l]{.smallcaps}-phenylalanine is transaminated to phenylpyruvate by amino transferase with 2-oxoglutarate (aKG) as the amine-receptor; (iii) phenylpyruvate is further decarboxylated to phenylacetaldehyde by phenylpyruvate decarboxylases; (iv) and finally, phenylacetaldehyde is reduced to 2-PE by alcohol dehydrogenases or phenylacetaldehyde reductase with NADH as cofactor.

In *Y. lipolytica*, transaminases and the phenylpyruvate decarboxylase are ylARO8 (encoded by gene *YALI0E20977g*) or ylARO9 (encoded by gene *YALI0C05258g*) and ylARO10 (encoded by gene *YALI0D06930g*), respectively. However, the specific [l]{.smallcaps}-phenylalanine permease and phenylacetaldehyde alcohol dehydrogenases have not been characterized. To determine the ability of *Y. lipolytica* in producing 2-PE, *Y. lipolytica* po1g (leu^--^) harboring an empty plasmid pYXLP′ (strain **po1g pYXLP′**) was used as control to incubate with different concentrations of [l]{.smallcaps}-phenylalanine (0, 2, 4, 6, 8, and 10 g/L) in shake flasks. Our results ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a) indicate that the highest titer of 2-PE reached 720.43 mg/L with 0.342 g/g~[l]{.smallcaps}-phenylalanine~ yield by adding 10 g/L [l]{.smallcaps}-phenylalanine, accompanying with 197.59 mg/L of byproduct phenylacetate. Considering economic efficiency (incomplete conversion of [l]{.smallcaps}-Phe), 4 g/L of [l]{.smallcaps}-phe was able to support 641.59 mg/L ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b) of 2-PE production with 0.339 g/g~[l]{.smallcaps}-phenylalanine~ yield ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}c). Thus, in the following work, 4 g/L of [l]{.smallcaps}-phe was determined for bioconversion.

![Initial assessment of using *Y. lipolytica* to produce 2-PE from [l]{.smallcaps}-phenylalanine *via* the Ehrlich pathway. (a--c) 2-PE and phenylacetate titer, time profiles of cell growth, and 2-PE yield of adding different concentrations [l]{.smallcaps}-phenylalanine (0, 2, 4, 6, 8, and 10 g/L). (d--f) 2-PE titer, yield, and cell growth of respective overexpressing genes *ylARO8*, *ylARO9*, and *ylARO10*. All experiments were performed in triplicate and error bars show standard deviation (SD). The \* indicates *p* \< 0.01, and \*\* indicates *p* \< 0.05 (two-tailed test).](sb9b00468_0002){#fig2}

Refactoring the Upstream Ehrlich Pathway to Improve 2-PE Yield {#sec2.2}
--------------------------------------------------------------

As suggested by the mathematical model ([Supplementary Note S1](http://pubs.acs.org/doi/suppl/10.1021/acssynbio.9b00468/suppl_file/sb9b00468_si_001.pdf)), improving the catalytic efficiency of the Ehrlich pathway and increasing aKG supplementation are the key determinants to improve 2-PE yield from [l]{.smallcaps}-phenylalanine. To refactor the Ehrlich pathway, we adopted a stepwise pathway engineering strategy. First, the native *ylARO8*, *ylARO9*, and *ylARO10* genes in Ehrlich pathway were overexpressed in *Y. lipolytica* po1g under the control of strong constitutive TEF-intron promoter. Shaking flask cultivation ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}d, and [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}e,f for cell growth and 2-PE yield) indicates that overexpression of *ylARO8* and *ylARO9* (strain **po1gP1** and **po1gP2**) has little effect on the 2-PE production. However, overexpression of *ylARO10* (strain **po1gP3**) increased 2-PE titer to 922.86 mg/L, about 33% higher than the control strain ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}d), suggesting that the reaction catalyzed by phenylpyruvate decarboxylase ylARO10 is a limiting-step in Ehrlich pathway. Thus, the ineffectiveness of overexpressing downstream genes (*ylARO8* or *ylARO9*) is likely due to the limited performance of the upstream ylARO10. Specifically, ylARO8 and ylARO9 are both transaminases, which catalyze the transamination of [l]{.smallcaps}-phenylalanine with different amine-receptors:[l]{.smallcaps}-Phenylalanine + 2-Oxoglutarate → Phenylpyruvate + [l]{.smallcaps}-Glutamate (catalyzed by YlARO8)[l]{.smallcaps}-Phenylalanine + Pyruvate → Phenylpyruvate + [l]{.smallcaps}-Alanine (catalyzed by YlARO9)

Apparently, different amine-receptors (that is 2-oxoglutarate and pyruvate) will lead to distinct outcomes (that is [l]{.smallcaps}-glutamate and [l]{.smallcaps}-alanine) that may affect 2-PE production. Therefore, we next constructed strains carrying pYLXP′-*ylARO10-ylARO8* and pYLXP′-*ylARO10-ylARO9* to identify the optimal transaminases, and obtained **po1gP4** and **po1gP5**. However, screening of these two strains showed no significant differences in 2-PE production ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b, and [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c,d for cell growth and 2-PE yield). We also overexpressed a transcriptional activator (encoded by YALI0C18645) to up-regulate the expression of *ylARO8* or *ylARO9*.^[@ref29]^ However, cultivation of this strain (**po1gP6**) showed deteriorated 2-PE production ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}b). With this, we speculated that cellular uptake of [l]{.smallcaps}-phe might be the bottleneck limiting 2-PE titer.

![Characterization of upstream module of the Ehrlich pathway: [l]{.smallcaps}-phenylalanine specific permeases and [l]{.smallcaps}-phe: 2-oxoglutarate transaminase. (a) Flow-chart of shake flask cultivations of engineered strains. (b--d) 2-PE titers, cell growth, and 2-PE yield of respective overexpressing genes *ylARO10* and *ylARO8*, *ylARO10* and *ylARO9*, and *ylARO10* and *C18645*. (e,f) 2-PE titers and 96h residual glucose of screening [l]{.smallcaps}-phenylalanine specific permeases with CSM fermentation medium in shake cultivations. All experiments were performed in triplicate and error bars show standard deviation (SD). The \* indicates *p* \< 0.01, and \*\* indicates *p* \< 0.05 (two-tailed test).](sb9b00468_0003){#fig3}

To facilitate the cellular uptake for [l]{.smallcaps}-phe, we assessed a number of [l]{.smallcaps}-phe permease, including BAP and Gap1 from *S. cerevisiae*,^[@ref34]^ PheP from *E. coli*, and three *Y. lipolytica* native Gap1 homologues, encoded by *YALI0C17237g* (named as *GapY1*), *YALI0B16522g* (*GapY2*), and *YALI0B19800g* (*GapY3*), respectively. Beyond our expectation, all the tested [l]{.smallcaps}-phe permeases showed decreased 2-PE production compared with control **po1gP4** and **po1gP5** when coupling with expression of *ylARO8-ylARO10* or *ylARO9-ylARO10* ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}e). Noticeably, abundant residual glucose was detected at 96 h ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}f), suggesting the central carbon metabolism of these strains was strongly inhibited. This result is consistent with the finding that high level of endogenous [l]{.smallcaps}-phe induces a strong down regulation of cellular metabolism in *S. cerevisiae*.^[@ref35]^ We reasoned that a similar effect might exist in *Y. lipolytica*. Thus, we dropped out all other amino acids and only used YNB-glucose with 4 g/L [l]{.smallcaps}-phe as the nitrogen source. As a result, the highest 2-PE titer reached 1632.73 mg/L with 0.547 g/g~[l]{.smallcaps}-phenylalanine~ yield in strain **po1gP4--6** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a,b) after 144 h cultivation, indicating GapY3 is a potent [l]{.smallcaps}-phe permease. Nevertheless, differences of 2-PE titers in strains **po1gP4--6** and **po1gP5--6** (1607.46 mg/L with 0.533 g/g~[l]{.smallcaps}-phenylalanine~) were insignificant, which may be attributed to the poor substrate specificity of transaminases ylARO8 and ylARO9.

![Characterization of the downstream module of the Ehrlich pathway: phenylacetaldehyde reductases and alcohol dehydrogenases. (a,b) 2-PE titers and yield by rescreening [l]{.smallcaps}-phenylalanine specific permeases. Red 1, strain **P4--1**; Red 2, strain **P4--2**; Red 3, strain **P4--3**; Red 4, strain **P4--4**; Red 5, strain **P4--5**; Red 6, strain **P4--6**; Black 1, strain **P5--1**; Black 2, strain **P5--2**; Black 3, strain **P5--3**; Black 4, strain **P5--4**; Black 5, strain **P5--5**; Black 6, strain **P5--6**. (c) Manipulations of whole-cell biocatalytic conversion of phenylacetaldehyde. PAH, phenylacetaldehyde. (d--g) 2-PE titers, cell growth and yield of screening and identifying the optimized phenylacetaldehyde reductases or alcohol dehydrogenases. P8--1, strain **po1gP8--1**; P8--2, strain **po1gP8--2**; P8--3, strain **po1gP8--3**; P8--4, strain **po1gP8--4**; P8--5, strain **po1gP8--5**; P8--6, strain **po1gP8--6**. All experiments were performed in triplicate and error bars show standard deviation (SD).](sb9b00468_0004){#fig4}

Refactoring the Downstream Ehrlich Pathway to Improve 2-PE Yield {#sec2.3}
----------------------------------------------------------------

To refactor the optimal alcohol dehydrogenase (ADH) or phenylacetaldehyde reductase (PAR), we screened the entire genome of *Y. lipolytica* with putative rose phenylacetaldehyde reductase PARL as the template, and identified eight PARs with high similarity (\>70%), encoded by *YALI0D08844g* (*PAR1*), *YALI0F09097g* (*PAR2*), *YALI0F24937g* (*PAR3*), *YALI0D07062g* (*PAR4*), *YALI0D12386g* (*PAR5*), *YALI0C20251g* (*PAR6*), *YALI0D11616g* (*PAR7*), and *YALI0D08778g* (*PAR8*), respectively. We also codon-optimized and synthesized the rose-derived *PARL* as a positive control. The resulting 9 strains, with overexpression of **PAR1**, **PAR2**, **PAR3**, **PAR4**, **PAR5**, **PAR6**, **PAR7**, **PAR8**, and **PARL**, were incubated with 1 g/L phenylacetaldehyde ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}c), leading to 2-PE titers of 762.71, 703.62, 759.37, 786.58, 435.61, 437.33, 399.11, 501.10, and 379.28 mg/L ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}d), respectively. The highest 2-PE titer was produced by strain **PAR4** (*YALI0D07062g*). Interestingly, the rose-derived PARL performed worst in our test.

Similarly, we also investigated the performances of alcohol dehydrogenases (ADHs) in *Y. lipolytica*. Nine *Y. lipolytica* ADHs annotated by Genbank (<https://www.ncbi.nlm.nih.gov/genbank/>) and GRYC (<http://gryc.inra.fr/>) were tested, including *ADH1* (*YALI0D25630g*), *ADH2* (*YALI0E17787g*), *ADH3* (*YALI0A16379g*), *ADH4* (*YALI0A15147g*), *ADH5* (*YALI0E07766g*), *ADH6* (*YALI0E15818g*), *ADH7* (*YALI0D02167g*), *ADH8* (*YALI1C17782g*), and *ADH9* (*SFA1*). The resulting strains were tested and only suboptimal level of 2-PE were detected in these strains compared to the strain harboring the optimal PARs ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}d), and the best strain (ADH2) produced 723.74 mg/L 2-PE, which is about 10% lower than strain **PAR4**.

After analyzing the downstream PAR and ADH modules, we chose six efficient candidates for further investigation, including ADH2, ADH3, PAR1, PAR2, PAR3, and PAR4. These PARs and ADHs were combined with the optimal upstream module *ylARO10-ylARO8-GapY3*, leading to strains **po1gP7--1**, **po1gP7--2**, **po1gP7--3**, **po1gP7--4**, **po1gP7--5**, and **po1gP7--6**. When tested in shake flask with YNB-glucose media and 4 g/L [l]{.smallcaps}-phenylalanine, these strains produced 2-PE at 1126.62, 902.12, 1109.89, 1166.23, 960.96, and 1378.98 mg/L, respectively ([Supplementary Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acssynbio.9b00468/suppl_file/sb9b00468_si_001.pdf)), representing no improvements in 2-PE titer compared to control **po1gP4--6** (ylARO10-ylARO8-GapY3, 1610.76 mg/L). We speculated that simultaneous overexpression of four genes (\>16 000 bp) may lead to genetic instability (loss of plasmid or unequal distribution/propagation of plasmid) in *Y. lipolytica*. To test this hypothesis, we linearized these plasmids and integrated the long DNA cassettes at the pBR docking site of po1g chromosome, leading to strains **po1gP8--1**, **po1gP8--2**, **po1gP8--3**, **po1gP8--4**, **po1gP8--5**, and **po1gP8--6**, respectively. Shake flask screening indicates that **po1gP8--6** produced 1750.46 mg/L of 2-PE with 0.534 g/g yield ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}f,g, and [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}e for cell growth), the highest titer obtained, indicating PAR4 is the optimal downstream module that reduces phenylacetaldehyde to 2-PE. So far, the four steps of the Ehrlich pathway (permeation, transamination, decarboxylation, and reduction) have been fully refactored, and the refactored pathway represents 2.4-fold increase in 2-PE titer over the starting strain (∼710 mg/L).

Blocking Competing Pathways to Improve 2-PE Titer {#sec2.4}
-------------------------------------------------

To further improve 2-PE yield, we attempted to delete the competing pathways. For the convenience of the genetic manipulations, we first knocked out gene *ku70* in po1f (named **po1fk**) to inhibit nonhomologous end joining (NHEJ) and improve the frequency of homologous recombination.

As mentioned above, the major byproduct is phenylacetate, which is the oxidized product of phenylacetaldehyde catalyzed by aldehyde dehydrogenases (ALD2 and ALD3). Thus, we sequentially knocked out both *ALD2* (*YALI0D07942g*) and *ALD3* (*YALI0F04444g*) in **po1fk**, obtaining strain **po1fk1**. Then the optimal upstream and downstream Ehrlich module *ylARO10-ylARO8-GapY3-PAR3* was integrated at the genome pBR docking site of **po1fk1**, obtaining strain **po1fk1P**. Although shake flask cultivation of **po1fk1P** showed no improvement in 2-PE titer, the byproduct phenylacetate was significantly decreased to 124.49 mg/L ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b, 532.48 mg/L phenylacetate in **po1gP8--6**).

![Blocking competitive pathways and integration of the Ehrlich pathway in 26s rDNA sites to improve 2-PE production. (a--c) Cell growth, 2-PE titers, phenylacetate titers, and 2-PE yield of blocking competitive pathways. (d) Screening of the productive strains based on 24-well deep plate cultivations. (e,f) 2-PE titer and yield by further validating productive strains with integration of the Ehrlich pathway in flask cultivations. 1, strain **po1fk4--1**; 2, strain **po1fk4--2**; 3, strain **po1fk4--3**; 4, strain **po1fk4--4**; 5, strain **po1fk4--5**; 6, strain **po1fk4--6**; 7, strain **po1fk4--7**; 8, strain **po1fk4--8**; 9, strain **po1fk4--9**; 10, strain **po1fk4--10**; 11, strain **po1fk4--11**; 12, strain **po1fk4--12**. All experiments were performed in triplicate and error bars show standard deviation (SD).](sb9b00468_0005){#fig5}

In addition, prephenate dehydratase PHA2 catalyzes the anaplerotic reaction from phenylpyruvate to prephenate ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Deletion of gene *PHA2* in strain **po1fk1** generated strain **po1fk2**. Chromosomally integrated (integrated at pBR docking site) Ehrlich module (*ylARO10-ylARO8-GapY3-PAR3*) in po1fk2 (strain **po1fk2P**) leads to an improved 2-PE titer of 1809.65 mg/L with the yield at 0.570 g/g~[l]{.smallcaps}-phenylalanine~ compared to **po1fk1P** ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b,c, 1735.78 mg/L with yield at 0.550 g/g~[l]{.smallcaps}-phenylalanine~), but a significant decrease in biomass was observed in **po1fk2P** ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}a). On the other hand, 4-hydroxyphenylpyruvate dioxygenase (encoded by gene y*lHPD*) could convert phenylpyruvate to 2-hydroxyphenylacetate. Therefore, we further knocked out y*lHPD* in strain **po1fk2**, obtaining strain **po1fk3**. However, the chromosomally integrated (integrated at pBR docking site) Ehrlich module in po1fk3 (strain **po1fk3P**) leads to decreased 2-PE production and increased phenylacetate titer, which were 1432.43 and 226.17 mg/L ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b), respectively. This result suggests that y*lHPD* cannot be knocked out in this scenario. It is not clear why the deletion of gene *ylHPD* has a negative result, possibly due to the incorrect annotation of the reaction directionality of *ylHPD*.

We have refactored the Ehrlich pathway and blocked the byproducts synthesis, and integrated the optimal gene module *ylARO10-ylARO8-GapY3-PAR3* to the pBR docking site of the triple knockout strain (**po1fk2**, ALD2, ALD3, and PHA2 were knocked out). In previous work, our group has established a 26s rDNA/Cre-*lox*P-based iterative gene integration and marker-curation method.^[@ref36]^ With more than 200 copies of ribosome DNAs in *Y. lipolytica*, this technique allows genes of interests to be randomly integrated into the genome with multiple copies. Thus, we next sought to apply this method and further optimize the Ehrlich pathway, including genes *ylARO10*, *ylARO8, GapY3*, and *PAR4*. To obtain a productive strain, we screened 144 genome-integrated transformants by 24-well deep plate cultivation in glucose-YNB medium with 4 g/L [l]{.smallcaps}-phenylalanine ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}d). About 45% of the genome-integrated produced 2-PE at 900--1000 mg/L, less than 5% of the screened strain produced 2-PE over 1200 mg/L. Then the top-performed strains were further validated in shake flasks ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}e,f). Strain **po1fk4--2** produced the highest 2-PE of 1817.46 mg/L with the yield at 0.590 g/g~[l]{.smallcaps}-phenylalanine~.

A Nonnative 2-Oxoglutarate (aKG) Shuttle to Improve Metabolite Trafficking {#sec2.5}
--------------------------------------------------------------------------

As suggested by the mathematical model ([Supplementary Note S1](http://pubs.acs.org/doi/suppl/10.1021/acssynbio.9b00468/suppl_file/sb9b00468_si_001.pdf)), we next sought to improve the precursor (2-oxoglutarate, aKG) flux. Noteworthily, *Y. lipolytica* is known for the strong TCA metabolic activity.^[@ref37]^ Indeed, we detected 4.84 g/L of citrate at 72 h of cultivation in strain **po1fk4--2** ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}b). Thus, rewiring the overflowed citrate flux to cytosolic aKG is a feasible strategy to increase precursor (aKG) supply and improve 2-PE production. Nevertheless, *Y. lipolytica* lacks the cytosolic aconitate hydratase and isocitrate dehydrogenase. To construct the cytosolic pathway from citrate to aKG ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}a), we introduced two aconitate hydratases, including CitB from *Bacillus subtilis* and AcnA from *E. coli*, and a cytosolic isocitrate dehydrogenase ScIDP2 from *S. cerevisiae*.^[@ref38]^ Additionally, by searching the genome of *Y. lipolytica* with ScIDP2 as template, we retrieved a putative cytosolic isocitrate dehydrogenase ylIDP2 (encoded by gene *YALI0F04095g*). Subsequently, four nonnative aKG source pathways, including *citB*-*scIDP2*, *citB*-*ylIDP2*, *acnA*-*scIDP2*, and *acnA*-*ylIDP2*, were introduced into **po1fk4--2** by plasmid pYLXP′. The resulting strains **po1fk4P1**, **po1fk4P2**, **po1fk4P3**, and **po1fk4P4** produced 1733.45, 2146.45, 1737.58, and 1842.85 mg/L of 2-PE with yield of 0.574, 0.606, 0.597, and 0.591 g/g~[l]{.smallcaps}-phenylalanine~ in shake flasks ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}c,d,e), respectively. It indicates the coexpression of *citB* and *ylIDP2* could effectively convert cytosolic citrate to aKG. In addition, we also overexpressed the mitochondrial 2-oxodicarboxylate carrier ylODC1 (encoded by gene *YALI0D02629g*) to export 2-oxoglutarate (aKG) out of the mitochondrial matrix to the cytosol (strain **po1fk4P5**, **po1fk4--2** harboring plasmid pYLXP′-*citB*-*ylIDP2-ylODC*). As expected, the 2-PE titer and yield in **po1fk4P5** were further increased, reaching 2269.08 mg/L and 0.632 g/g~[l]{.smallcaps}-phenylalanine~ ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}a,b,c), respectively.

![Overcoming cellular compartmentalization of 2-oxoglutarate (aKG) to increase aKG availability. (a) Construction of cytosolic source for 2-oxoglutarate synthesis by coupling bacterial aconitase with the overflowed citrate from Krebs cycle. (b) Citrate titers of strain **po1fk4--2**. (c--e) 2-PE titers, cell growth and yield of strains **po1fk4P1**, **po1fk4P2**, **po1fk4P3**, and **po1fk4P4**. All experiments were performed in triplicate and error bars show standard deviation (SD).](sb9b00468_0006){#fig6}

![Improving 2-oxoglutarate trafficking across the mitochondria membrane by overexpressing the mitochondrial 2-oxodicarboxylate carrier ylODC1 and improving 2-PE titer by blocking fatty acid synthesis. (a--d) 2-PE titers, cell growth, yield, and lipid titers of strains **po1fk4P5**, **po1fk5P**, **po1fk6P**, and **po1fk7P**. All experiments were performed in triplicate and error bars show standard deviation (SD). The \* indicates *p* \< 0.01 (two-tailed test).](sb9b00468_0007){#fig7}

On the other hand, *Y. lipolytica* is known to accumulate up to 30--60% dry cell weight as lipid.^[@ref10],[@ref39]^ As shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b, production of 1 mol of fatty acids (stearic acids C18:0) will consume 16 mol of NADPH and 9 mol of citrate (acetyl-CoA). As a result, the synthesis of lipid competes with aconitase (aconitate hydratases) and PARs for cytosolic citrate and NADPH. Specially, diacylglycerol acyltransferases have been identified as the rate-limiting steps to lipid synthesis *via* the Kennedy pathway in *Y. lipolytica*.^[@ref40],[@ref41]^ Thus, we pursued further to knock out the diacylglycerol acyltransferases, encoded by *ylDGA1* (*YALI0E32769g*) and *ylDGA2* (*YALI0D07986g*), to mitigate fatty acid synthesis. Shake flask cultivation of the resulting strain **po1fk5P** (po1fk4--2 *ΔylDGA1::loxP* harboring pYLXP′-*citB*-*ylIDP2-ylODC*), **po1fk6P** (po1fk4--2 *ΔylDGA2::loxP* harboring pYLXP′-*citB*-*ylIDP2-ylODC*), and **po1fk7P** (po1fk4--2 *ΔylDGA2 ΔylDGA1::loxP* harboring pYLXP′-*citB*-*ylIDP2-ylODC*) all led to significant improvements in 2-PE titers and yield ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}a,b,c). Specifically, strain **po1fk7P** produced 2669.54 mg/L of 2-PE with yield at 0.702 g/g~[l]{.smallcaps}-phenylalanine~ ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}a,b,c), which was 1.11-fold and 1.18-fold higher than strain **po1fk4P5**. Furthermore, to validate the impacts of *ylDGA1* and *ylDGA2* deletion on lipid production, we measured the lipid titer in strains **po1fk4P5**, **po1fk5P**, **po1fk6P**, and **po1fk7P** ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}d), reaching 3.93, 2.06, 2.08, and 1.84 g/L, respectively. These results confirmed that fatty acid synthesis was indeed mitigated by deleting genes *ylDGA1* and *ylDGA2*. In conclusion, by constructing a cytosolic aKG pathway and expression of the dicarboxylic acid transporter (ylODC) as well as mitigating fatty acids synthesis, we efficiently improved the aKG flux and 2-PE tier and yield.

Conclusions {#sec3}
===========

Efficient microbial synthesis of chemicals necessitates systematic debottlenecking, refactoring and optimization of the native or nonnative metabolic pathways. With 2-PE as a tested molecule, we analyzed the stoichiometric constraints of the Ehrlich pathway toward efficient synthesis of the target molecules in *Y. lipolytica*. The proposed metabolic model reveals potential engineering targets for high yield production of 2-PE with cosubstrate feeding of glucose and [l]{.smallcaps}-phenylalanine. Specifically, guided by the model, we identified that the catalytic efficiency of the Ehrlich pathway and the precursor 2-oxoglutarate (aKG) supplement might be the rate-limiting steps. Stepwise refactoring the Ehrlich pathway and overcoming the cellular compartmentalization of precursor (aKG) significantly improved 2-PE production. By blocking the precursor-competing pathways and mitigating fatty acids synthesis, the engineered strain produced 2669.54 mg/L of 2-PE with yield at 0.702 g/g in shake flasks, which were 4.16 and 2.07-fold of the starting strain, respectively. The strategies reported in this study should be adding value and guide us to engineer other complex metabolic pathways for various biomanufacturing applications.

Further investigations on relieving 2-PE toxicity and promoting cell fitness are viable solutions to improve 2-PE production. Major considerations should include 2-PE tolerance/toxicity, medium composition, and optimal fermentation processes. In general, mutagenesis coupled with high throughput screening is an efficient and convenient way to evolve tolerance phenotype.^[@ref42]^ In addition, small amounts of organic nitrogen sources, such as peptone and yeast extract, benefit cell growth without inhibiting the Ehrlich pathway.^[@ref43]^ Moreover, it was found that both Ca^2+^ and Mg^2+^ salts protect the cell and facilitate 2-PE production by increasing membrane stability and integrity.^[@ref44]^ Besides, by adding organic solvents as overlays during fermentation, 2-PE titer could be increased to 12.6 g/L in the concentrated organic layer.^[@ref45]^ These strategies will enable us to build a sustainable 2-PE platform at low cost and high efficiency.

Materials and Methods {#sec4}
=====================

Strains, Plasmid, Primers, and Chemicals {#sec4.1}
----------------------------------------

All strains of engineered *Y. lipolytica*, including the genotypes of manipulations, recombinant plasmids, and primers, have been listed in [Supplementary Table S1 and S2](http://pubs.acs.org/doi/suppl/10.1021/acssynbio.9b00468/suppl_file/sb9b00468_si_001.pdf). Chemicals used in this study include phenylacetaldehyde, [l]{.smallcaps}-phenylalanine, phenylacetate, 2-phenylethanol, 2-oxoglutarate, and citrate, which were all purchased from Sigma-Aldrich.

Shake Flask and 24-Wells Deep-Plate Cultivations {#sec4.2}
------------------------------------------------

All engineered strains were underwent optimal screening before shake flask cultivations (see [Yeast Transformation and Screening of High-Producing Strains](#sec4.4){ref-type="other"}, [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a). For shake flask cultivations, seed culture was carried out in the shaking tube with 2 mL seed culture medium at 30 °C and 250 r.p.m. for 48 h. Then, 0.8 mL of seed culture was inoculated into the 250 mL flask containing 35 mL of fermentation medium and grown under the conditions of 30 °C and 250 r.p.m. for 144 h. One milliliter of cell suspension was sampled every 24 h for OD~600~, glucose, 2-PE, [l]{.smallcaps}-phenylalanine, and penylacetate measurements. For performing 24-well deep-plate cultivation, engineered *Y. lipolytica* strains were first cultured in 96-wells pales with 150 μL seed culture medium at 30 °C and 1000 r.p.m. for 36 h. Sequentially, 40 μL of seed culture was inoculated to the 24-well deep plate with 2 mL fermentation medium at 30 °C and 1000 r.p.m. for 96 h, and finally, 1 mL of cell suspension was sampled for 2-PE, [l]{.smallcaps}-phenylalanine, and penylacetate measurements.

The seed culture medium used in this study was the yeast complete synthetic media regular media CSM containing the following: glucose 20.0 g/L, yeast nitrogen base (without ammonium sulfate) 1.7 g/L, ammonium sulfate 5.0 g/L, and CSM-Leu or CSM-Ura 0.74 g/L. Two types of fermentation medium were used in our work, including nitrogen-limited media CSM and YNB. The nitrogen-limited media CSM contained the following: glucose 40.0 g/L, yeast nitrogen base (without ammonium sulfate) 1.7 g/L, ammonium sulfate 1.1 g/L, CSM-Leu 0.74 g/L, and appropriate [l]{.smallcaps}-phenylalanine. The nitrogen-limited media YNB contained the following: glucose 40.0 g/L, yeast nitrogen base (without ammonium sulfate) 1.7 g/L, leucine or uracil 0.2 g/L, and appropriate [l]{.smallcaps}-phenylalanine.

Whole-Cell Bioconversion of Phenylacetaldehyde {#sec4.3}
----------------------------------------------

To prepare the whole-cell biocatalyst, cells were harvested during the exponential growth phase (48 h) from the shake flask cultivation. Then, cells were washed twice with 100 mM phosphate buffer (pH 7.0), and resuspended to an OD~600~ of 4 in the same buffer. Next, whole-cell biocatalytic conversion of phenylacetaldehyde was performed in 20-ml glass tube containing 1 mL of cell suspension (OD~600~ = 4) and 1 mL phenylacetaldehyde--water solution (2 g/L phenylacetaldehyde) at 30 °C and 250 r.p.m. for 4 h. One hundred microliters of cell suspension was sampled every 1 h for 2-PE and penylacetate measurements.

Yeast Transformation and Screening of High-Producing Strains {#sec4.4}
------------------------------------------------------------

The standard protocols of *Y. lipolytica* transformation by the lithium acetate method were described as previously reported.^[@ref36],[@ref46]^ In brief, 1 mL of cells was harvested during the exponential growth phase (16--24 h) from 2 mL YPD medium (yeast extract 10 g/L, peptone 20 g/L, and glucose 20 g/L) in the 14 mL shake tube, and washed twice with 100 mM phosphate buffer (pH 7.0). Then, cells were resuspended in 105 μL transformation solution, containing 90 μL 50% PEG4000, 5 μL lithium acetate (2 M), 5 μL boiled single stand DNA (salmon sperm, denatured), and 5 μL DNA products (including 200--500 ng of plasmids, lined plasmids or DNA fragments), and incubated at 39 °C for 1 h, then spread on selected plates. It should be noted that the transformation mixtures needed to be vortexed for 15 s every 15 min during the process of 39 °C incubation. The selected markers, including leucine and uracil, were used in this study. All engineering strains after genetic manipulations were performed optimized screening by the shaking tube cultivations, and the optimal strain was used to perform shaking flask (these data have been shown in [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acssynbio.9b00468/suppl_file/sb9b00468_si_001.pdf)).

Expression Vectors Construction and Pathway Assembly {#sec4.5}
----------------------------------------------------

The YaliBrick plasmid pYLXP′ was used as the expression vector in this study.^[@ref47],[@ref48]^ Plasmid constructions were performed by using preciously described methods.^[@ref36],[@ref49]^ In brief, recombinant plasmids of pYLXP′-*XX* (a single gene expression) were obtained by Gibson Assembly method^[@ref50]^ using linearized pYLXP′ (digested by *SnaBI* and *Kpn*I) and the appropriate PCR-amplified DNA fragment. Multigenes assembly was achieved by restriction enzyme digestion subcloning based on the application of isocaudamers *AvrII* and *NheI*.^[@ref47],[@ref51]^ All genes were respectively expressed by the TEF promoter with intron sequence and XPR terminator. The modified DNA fragments and plasmids were sequenced by Quintarabio. The endonucleases used in this research were purchased from Thermo Fisher Scientific or NEB.

Gene Knockout and 26s rDNA Genomic Integration of Ehrlich Pathway {#sec4.6}
-----------------------------------------------------------------

A marker-free gene knockout method based on Cre-*lox* recombination system was used as previously reported.^[@ref52]^ For performing gene knockout, the upstream and downstream sequences (both 1000 bp) flanking the deletion targets were PCR-amplified. These two fragments, the *loxP-URA-loxP* cassette (digested from plasmid pYLXP′-*loxp-URA* by *AvrII* and *salI*), and the residual plasmid backbone of pYLXP′-*loxp-URA* were joined by the Gibson Assembly method, obtaining the gene knockout plasmids pYLXP′-*loxP-URA-XX.* The obtained plasmids were sequenced by Quintarabio. Next, the gene knockout cassettes were PCR-amplified from construction plasmids pYLXP′-*loxp-URA-XX*, and further transformed into *Y. lipolytica*. The positive transformants were determined by colony PCR. Next, plasmid pYLXP′-*Cre* was introduced into the positive transformants and promoted the recombination of *loxP* sites, which recycle the selected marker. Finally, the intracellular plasmid pYLXP′-*Cre* was evicted by incubation at 30 °C for 48 h.

The standard protocol of 26s rDNA genomic integration also has been described in previous reported.^[@ref36]^ For 26s rDNA genomic integration of the Ehrlich pathway, the expression plasmid pYLXP′-*ylARO10-ylARO8-GapY3-PAR4* was digested by *AvrII* and *NotI*, and the fragment containing the Ehrlich pathway was inserted into linearized pYLXP′-*loxp-URA* digested by *Nhel* and *NotI*, getting pYLXP′-*loxp-URA-ylARO10-ylARO8-GapY3-PAR4*. The homologous arms of 26s rDNA, including 26s rDNA 1s and 2s, were PCR-amplified by appropriate primers. And next, these two homologous-arm fragments, Ehrlich pathway with the *loxP-URA-loxP* cassette (digested from plasmid pYLXP′-*loxp-URA-ylARO10-ylARO8-GapY3-PAR4* by *AvrII* and *NotI*), and the residual plasmid backbone of pYLXP′-*loxp-URA-ylARO10-ylARO8-GapY3-PAR4* were joined by Gibson Assembly method, obtaining the 26s rDNA genomic integration plasmids prDNAloxP*-ylARO10-ylARO8-GapY3-PAR4.* Then, the 26s rDNA genomic integration cassette of the Ehrlich pathway was gotten by digesting prDNAloxP*-ylARO10-ylARO8-GapY3-PAR4* with *AvrII* and *NotI*, and the integration cassette was further transformed into *Y. lipolytica*. In addition, the manipulation of recycling the selected marker was similar to gene knockout.

Quantification of Cell Density, 2-PE, Penylacetate, [l]{.smallcaps}-Phenylalanine, Glucose, Citrate, Fatty Acid, and Y~2-PE~ Calculation {#sec4.7}
----------------------------------------------------------------------------------------------------------------------------------------

Cell densities were monitored by measuring the optical density at 600 nm (OD~600~). The concentrations of 2-PE, penylacetate, and [l]{.smallcaps}-phenylalanine were measured by high-performance liquid chromatography (HPLC) through Agilent HPLC 1220 equipped with a ZORBAX Eclipse Plus C18 column (4.6 × 100 mm, 3.5 μm, Agilent) and a VWD detector. The analysis was performed at 215 nm under 40 °C column temperature with a mobile phase comprising 50% (v/v) methanol in water at a flow rate of 0.5 mL/min. The concentrations of glucose and citrate were also measured by Agilent HPLC 1220 equipped with a Supelcogel Carbohydrate column (Sigma, USA) and a refractive index detector. H~2~SO~4~ (5 mM) was used as the mobile phase at a flow rate of 0.6 mL/min at 40 °C. The method of quantification of fatty acid was used as previously reported.^[@ref39]^ Y~2-PE~ is the 2-PE yield relative to the consumption of [l]{.smallcaps}-phenylalanine.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acssynbio.9b00468](https://pubs.acs.org/doi/10.1021/acssynbio.9b00468?goto=supporting-info).Supplementary Table S1. Strains and plasmids; Supplementary Table S2. Primers and Oligos; Supplementary Table S3. Strain performance; Supplementary Note. Stoichiometric model to assess Ehrlich pathway efficiency; Supplementary Figure S1. Stoichiometric models reveal that 2-PE yield is driven by selectivity of the Ehrlich pathway and supply of 2-oxoglutarate (aKG); Supplementary Figure S2. 2-PE titers of screening [l]{.smallcaps}-phenylalanine specific permeases with the addition of final concentration of 4g/L [l]{.smallcaps}-phenylalanine into CSM fermentation medium (48 h) in shake cultivations; Supplementary Figure S3. 2-PE titers of strain strains po1gP7--1, po1gP7--2, po1gP7--3, po1gP7--4, po1gP7--5, and po1gP7--6 in shake cultivations ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acssynbio.9b00468/suppl_file/sb9b00468_si_001.pdf))

Supplementary Material
======================

###### 

sb9b00468_si_001.pdf

PX and YG conceived the topic. YG developed the models, performed genetic engineering and fermentation experiments with input from JM and YZ. YG and PX wrote the manuscript.

The authors declare no competing financial interest.

This work was supported by the Cellular & Biochemical Engineering Program of the National Science Foundation under grant no. 1805139 and the Bill & Melinda Gates Foundation under grant no. OPP1188443. YG would like to thank the School of Biotechnology in Jiangnan University for funding support.
